Extended Data Fig. 6: Loss of Slc7a5 in Lgr5-positive cells does not alter Apc tumorigenesis or mTORC1 signaling.
From: The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
a, Kaplan–Meier survival curve of Lgr5CreER Apcfl/fl Slc7a5+/+ and Lgr5CreER Apcfl/fl Slc7a5fl/fl mice aged until clinical endpoint (Lgr5CreER Apcfl/fl Slc7a5+/+, n = 9; Lgr5CreER Apcfl/fl Slc7a5fl/fl, n = 15). P = 0.1860, log-rank (Mantel–Cox) test. b, Boxplot showing total number of tumors from Lgr5CreER Apcfl/fl and Lgr5CreER Apcfl/fl Slc7a5fl/fl mice aged until clinical endpoint. Lgr5CreER Apcfl/fl, n = 9; Lgr5CreER Apcfl/fl Slc7a5fl/fl, n = 15. Box depicts the interquartile range, central line indicates the median and whiskers indicate minimum/maximum values. c, Representative H&E, BrdU, pS6 and peEF2 staining of tumors from Lgr5CreER Apcfl/fl Slc7a5+/+ and Lgr5CreER Apcfl/fl Slc7a5fl/fl mice (representative of three biologically independent mice for each genotype). Scale bar, 100 μm. d, Representative pmTOR, peEF2 and p4EBP1 staining in Apcfl/+ KrasG12D/+ Slc7a5+/+ and Apcfl/+ KrasG12D/+ Slc7a5fl/fl tumors (representative of three biologically independent mice for each genotype). Dashed boxes highlight selected areas shown in high magnification. Scale bar, 100 μm.
